A new study published in Nature Neuroscience reveals that optogenetic activation of vasoactive intestinal polypeptide (VIP) inhibitory neurons can restore normal brain function in a mouse model of Huntington's disease. The research identifies a specific circuit defect in the striatum—a brain region critical for movement control—that may underlie some motor symptoms of the disorder.
VIP neurons normally suppress overactive medium spiny neurons, and in Huntington's mice this inhibition is lost. By using light to activate these VIP neurons, researchers were able to rebalance neural activity and restore motor function in the animals. The study was led by a team at the University of California, San Francisco and published in Nature Neuroscience on February 27.
The approach remains strictly preclinical. Optogenetics is not yet approved for human use, and translating this technique into a therapy would require significant advances in gene therapy and device implantation. No clinical trials are currently planned.
Huntington's disease is a fatal genetic neurodegenerative disorder affecting about 30,000 people in the United States. Existing treatments only manage symptoms, but this work provides a new cellular target—VIP neurons—that could lead to future circuit-based therapies. The company involved, if any, was not disclosed in the source.
Experts caution that while the findings are compelling, mouse models do not perfectly replicate human Huntington's disease. The study's senior author noted that further research is needed to determine whether VIP neuron dysfunction occurs in patients and whether it can be safely modulated without causing side effects.